Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
2019年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2019年度独立董事述职报告' which translates to '2019 Independent Directors' Report'. It details the independent directors' duties, attendance, committee work, and evaluations for the year 2019. It includes information about board and committee meetings, internal control, related party transactions, and changes in directors and senior management. The document is a detailed report on the activities and responsibilities of the independent directors rather than a general annual report or financial statement. It focuses on board/management information, specifically the independent directors' performance and governance role. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2020-04-28 Chinese
独立董事关于第一届董事会第十五次会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several proposals related to the company's board meeting, including profit distribution, appointment of senior management, remuneration plans, and appointment of the audit firm for the next fiscal year. It references compliance with company law, governance guidelines, and company articles. The document does not contain financial statements or detailed financial data but rather opinions and approvals related to governance and management decisions. It is not a full annual report, audit report, or financial report. The content aligns with Board/Management Information (MANG) as it discusses appointments and governance matters related to senior management and audit firm selection.
2020-04-28 Chinese
关于聘任公司高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of senior management personnel at 百奥泰生物制药股份有限公司. It details the names, qualifications, and roles of newly appointed vice general managers. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses solely on management changes. According to the filing definitions, announcements about changes in senior management fall under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the correct classification is MANG with high confidence.
2020-04-28 Chinese
2019年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2019年度董事会审计委员会履职报告" which translates to the "2019 Annual Board Audit Committee Performance Report." It details the activities, meetings, and evaluations conducted by the audit committee during the 2019 fiscal year. The content includes oversight of external auditors, internal audit guidance, review of financial reports, and internal control evaluations. It is a report on the audit committee's duties and performance rather than a full annual report or standalone audit report. The document length is 2767 characters, which is relatively short but contains substantive content about audit committee activities rather than just an announcement. This fits best under the category of Audit Report / Information (AR), as it is a standalone audit-related report focusing on audit committee duties and evaluations, not the full annual report or a simple announcement. FY 2019
2020-04-28 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of 百奥泰生物制药股份有限公司, including the date, voting methods, meeting agenda, and instructions for shareholders. It lists the proposals to be voted on, such as the 2019 annual report, board work report, auditor appointment, profit distribution, and amendments to company articles. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. The document length is 4171 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-28 Chinese
关于获得政府补助的公告
Capital/Financing Update Classification · 90% confidence The document is a short announcement (461 characters) regarding the receipt of a government subsidy by the company 百奥泰生物制药股份有限公司. It describes the nature of the subsidy and its accounting treatment but does not contain any financial statements or detailed financial data. It is an update on a financing-related event but not a full capital or financing report. Given the short length and content, it is an announcement about a capital-related event (government subsidy) rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2020-03-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.